Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 640Glioblastoma 573Glioma 407Neuroblastoma 174Neoplasms 125Astrocytoma 107Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 85Carcinoma, Non-Small-Cell Lung 78Melanoma 76Lung Neoplasms 70Sarcoma 65Ependymoma 64Neurofibromatosis 1 62Recurrence 50Neoplasm Metastasis 48Oligodendroglioma 47Meningeal Carcinomatosis 47Osteosarcoma 46Diffuse Intrinsic Pontine Glioma 45Rhabdomyosarcoma 44Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Pancreatic Neoplasms 39Sarcoma, Ewing 38Colorectal Neoplasms 33

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × CNS × 1 year × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡